header

Obesity-news.com
THE LATEST IN OBESITY RESEARCH AND WEIGHTLOSS DRUG DEVELOPMENT

    Join our list More information

    

Xenical and alli

XENICAL COMPANY INFORMATION
Xenical 120 mg  

Hoffmann-LaRoche Web Sites

Other information



Last updated October 27, 2007. Xenical (orlistat) is a drug that works locally in the gastrointestinal tract to inhibit the absorption of fat. It is a synthetic derivative of lipostatin, a naturally occurring lipase inhibitor ("fat blocker") which binds to gastric and pancreatic lipase, two digestive enzymes. Xenical also inhibits other digestive enzymes, including some found outside the gastrointestinal tract. When orlistat is taken with fat-containing foods, the fat passes through the gastrointestinal tract unchanged, and the calories are not absorbed. Pancreatic lipase reacts with the orlistat to reduce the absorption of about 30 percent of dietary fat, resulting in a reduction of approximately 200 calories per day. For patients who cannot take centrally acting appetite suppressants, Alli (prounced ally) is a half dose version of Xenical which was approved in 2007 for over-the-counter use.

Unfortunately, Xenical is associated with a lot of unpleasant side effects which include flatulence and abdominal cramps, fecal incontinence and oily spotting. Gastrointestinal (GI) side effects are the most common reason why patients discontinue this drug, and also why sales of Xenical have been less than anticipated even with additional approvals for its use in adolescent obesity and reduction in diabetes risk. The good news is that several second generation lipase inhibitors are in development. The most advanced of these compounds is cetilistat, which in extensive phase II testing has been shown to have a similar weight loss profile to Xenical -- without the GI side effects.

ALLI COMPANY INFORMATION
 

GSK Web sites

Other information



OTC version Xenical approved. For patients interested in an over-the-counter (OTC) version of Xenical, the FDA approved Alli on February 7, 2007. The consumer health care group of GlaxoSmithKline acquired the rights in 2004 to market the reduced dose (60 mg) OTC formula.

  • FDA approves orlistat for over-the-counter use. FDA press release, February 7, 2007.
  • FDA Joint Advisory Committee recommends approval of orlistat 60 MG capsules for over-the-counter use. GlaxoSmithKline press release, January 23, 2005.
  • FDA Joint Advisory Committee sets date to review GlaxoSmithKline Consumer Healthcare’s proposal for Orlistat 60 (MG) capsules for over-the-counter use. GlaxoSmithKline press release, December 9, 2005.

header

Obesity-news is a publication of Hirsch Communications. An on-line subscription is $104.00 per month, payable in advance by American Express, VISA or Mastercard. Subscribing is simple using our secure on-line subscription form. A yearly subscription is also available for $1040 per year through EBSCO or Swets Blackwell subscription services. Please contact them for more information. Obesity-news also accepts fax orders at 703/960-7462. Copyright 1997-2013, all rights reserved.

IMPORTANT: All information in this publication is believed to be accurate and true. Publisher is not liable for omissions or inaccuracies. Information in this newsletter is for educational purposes only and should not be construed as medical advice, or be used in lieu of consultation with a health care provider.